U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H16O11
Molecular Weight 468.3665
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CROMOLYN

SMILES

OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC3=CC=CC4=C3C(=O)C=C(O4)C(O)=O

InChI

InChIKey=IMZMKUWMOSJXDT-UHFFFAOYSA-N
InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)

HIDE SMILES / InChI

Molecular Formula C23H16O11
Molecular Weight 468.3665
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Cromolyn is a mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells, which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Cromolyn is indicated in the management of patients with mastocytosis, prophylaxis (long-term control) of bronchial asthma, prevention of exercise-induced bronchospasm, prevention and treatment of seasonal and perennial allergic rhinitis The most frequently reported adverse reactions attributed to cromolyn sodium treatment were: throat irritation or dryness, bad taste, cough, wheeze, nausea.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
19.0 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CROMOLYN SODIUM
Preventing
CROMOLYN SODIUM
Palliative
CROMOLYN SODIUM
Primary
CROMOLYN SODIUM
Preventing
CROMOLYN SODIUM
Preventing
NASALCROM
Palliative
OPTREX

Cmax

ValueDoseCo-administeredAnalytePopulation
0.24 ng/mL
17.1 mg single, respiratory
CROMOLYN cerebrospinal fluid
Homo sapiens
0.34 ng/mL
34.2 mg single, respiratory
CROMOLYN cerebrospinal fluid
Homo sapiens
46.69 ng/mL
17.1 mg single, respiratory
CROMOLYN plasma
Homo sapiens
96.75 ng/mL
34.2 mg single, respiratory
CROMOLYN plasma
Homo sapiens
156 ng/mL
40 mg single, oral
CROMOLYN plasma
Homo sapiens
236 ng/mL
80 mg single, oral
CROMOLYN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
338 ng × h/mL
40 mg single, oral
CROMOLYN plasma
Homo sapiens
526 ng × h/mL
80 mg single, oral
CROMOLYN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.8 h
17.1 mg single, respiratory
CROMOLYN plasma
Homo sapiens
1.8 h
34.2 mg single, respiratory
CROMOLYN plasma
Homo sapiens

Doses

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Two metered inhalations four times daily at regular intervals (asthma).
Route of Administration: Respiratory
In Vitro Use Guide
Cromoglycate (the active component of cromoglicate lisetil) significantly inhibits histamine release from lung and tonsillar mast cells at 1000 uM.
Substance Class Chemical
Record UNII
Y0TK0FS77W
Record Status Validated (UNII)
Record Version